Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methimazole
Drug ID BADD_D01414
Description Methimazole is a thionamide antithyroid agent that inhibits the synthesis of thyroid hormones.[A184559,A184733,A184694] It was first introduced as an antithyroid agent in 1949[A184502] and is now commonly used in the management of hyperthyroidism, particularly in those for whom more aggressive options such as surgery or radioactive iodine therapy are inappropriate.[L8336,L8339] On a weight basis, methimazole is 10 times more potent than the other major antithyroid thionamide used in North America, [propylthiouracil],[L8339] and is the active metabolite of the pro-drug [carbimazole], which is an antithyroid medication used in the United Kingdom and parts of the former British Commonwealth.[A184733] Traditionally, methimazole has been preferentially used over propylthiouracil due to the risk of fulminant hepatotoxicity carried by the latter,[A184757] with propylthiouracil being preferred in pregnancy due to a perceived lower risk of teratogenic effects. Despite documented teratogenic effects in its published labels,[L8336,L8339] the true teratogenicity of methimazole appears to be unclear[A184643,A184757,A184763] and its place in therapy may change in the future.
Indications and Usage For the treatment of hyperthyroidism, goiter, Graves disease and psoriasis.
Marketing Status Prescription; Discontinued
ATC Code H03BB02
DrugBank ID DB00763
KEGG ID D00401
MeSH ID D008713
PubChem ID 1349907
TTD Drug ID D0S4BR
NDC Product Code 68071-5197; 38779-0360; 60429-380; 63629-2027; 63629-8347; 64980-260; 51927-1943; 71335-0883; 63629-9250; 63629-2026; 63629-9137; 50090-3334; 60687-357; 23155-070; 60429-381; 49884-640; 70518-1506; 63629-9251; 50090-2366; 51552-0822; 62991-1515; 70518-1475; 62135-206; 60687-370; 63629-2225; 66219-0253; 63629-9249; 0185-0205; 0185-0210; 54382-112; 23155-071; 63629-2224; 49884-641; 62135-205; 49452-4573; 64980-261; 63629-6408
Synonyms Methimazole | 1-Methyl-2-mercaptoimidazole | 1 Methyl 2 mercaptoimidazole | Merkazolil | Tiamazol | Thiamazole | Thimazol | Mercasolyl | Mercazolyl | Methymazol | Methylmercaptoimidazole | Mercazol | Mercazole | Metisol | Metizol | Tapazole | Tirodril | Strumazol | Thiamazol Henning | Henning, Thiamazol | Thiamazol Hexal | Hexal, Thiamazol | Thyrozol | Favistan | Methizol
Chemical Information
Molecular Formula C4H6N2S
CAS Registry Number 60-56-0
SMILES CN1C=CNC1=S
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Insulin autoimmune syndromeHLA class II histocompatibility antigen, DRB1 beta chainP01911Not Available8064238; 11751969; 7604034; 9119530; 15711804; 10233671; 7679413; 7519208; 11290778
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pancreatitis acute07.18.01.0020.003249%Not Available
Pancytopenia01.03.03.0030.001554%Not Available
Paraesthesia17.02.06.005--
Pericardial effusion02.06.01.0020.002166%
Pleural effusion22.05.02.0020.007580%
Pneumonia22.07.01.003; 11.01.09.0030.003790%Not Available
Pneumothorax22.05.02.0030.001624%
Polyarteritis nodosa24.05.02.011; 20.01.02.004; 15.06.01.003; 10.02.02.001--Not Available
Polyarthritis15.01.01.0050.005956%Not Available
Premature baby18.04.02.0010.002166%Not Available
Premature delivery18.07.01.0060.001083%
Pruritus23.03.12.0010.004331%
Pulmonary alveolar haemorrhage24.07.01.015; 22.01.02.0050.003790%Not Available
Pyrexia08.05.02.0030.008121%
Rash23.03.13.0010.004331%Not Available
Rash erythematous23.03.06.0030.001083%Not Available
Rash generalised23.03.13.0020.001083%Not Available
Rash macular23.03.13.0030.001083%Not Available
Rectal haemorrhage24.07.02.018; 07.12.03.0010.001083%
Renal tubular necrosis20.01.07.0030.001083%Not Available
Respiratory distress22.02.01.0120.001083%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.002707%
Retinal vasculitis10.02.02.021; 06.04.06.0110.002707%Not Available
Rhabdomyolysis15.05.05.0020.004331%
Sepsis11.01.11.0030.000989%
Septic shock24.06.02.011; 11.01.11.0040.000847%Not Available
Serum sickness12.02.08.004; 10.01.03.0040.001624%
Somnolence19.02.05.003; 17.02.04.006--
Syncope24.06.02.012; 17.02.04.008; 02.01.02.0080.001624%
Systemic candida11.03.03.0160.000424%Not Available
The 4th Page    First    Pre   4 5 6    Next   Last    Total 6 Pages